Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: A UK perspective

Journal of Medical Economics

Volumn 19, Issue 3, 2016, Pages 236-242

  Roze, Stéphane ^a   Smith Palmer, Jayne ^b   Valentine, William J ^b   Cook, Mark ^c   Jethwa, Manisha ^c   De Portu, Simona ^d   Pickup, John C ^e  

^a HEVA HEOR   (France)

^b Ossian Health Economics and Communications   (Switzerland)

^c Medtronic Ltd   (United Kingdom)

^d Medtronic International Trading Sarl   (Switzerland)

^e GUY S HOSPITAL   (United Kingdom)

Author keywords

Continuous glucose monitoring; Continuous subcutaneous insulin infusion; Cost effectiveness; Sensor augmented pump therapy; Type 1 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT;

ADULT; AMPUTATION; ANGINA PECTORIS; ARTICLE; BLOOD GLUCOSE MONITORING; CATARACT; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CONTINUOUS SUBCUTANEOUS INSULIN INFUSION; COST EFFECTIVENESS ANALYSIS; END STAGE RENAL DISEASE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE SENSOR; GLYCEMIC CONTROL; HEALTH ECONOMICS; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; LIFE EXPECTANCY; MACULAR EDEMA; MALE; MICROALBUMINURIA; NEUROPATHY; PERIPHERAL VASCULAR DISEASE; PROLIFERATIVE RETINOPATHY; PROTEINURIA; QUALITY ADJUSTED LIFE YEAR; SENSOR AUGMENTED PUMP; ULCER; VISUAL IMPAIRMENT; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; ECONOMICS; MONTE CARLO METHOD; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; BLOOD GLUCOSE SELF-MONITORING; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS;

EID: 84959096594     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1113979     Document Type: Article

References (43)

1. Hammond P. Improving access to insulin pump therapy: the role of the Insulin Pump Network. J Diabetes Nursing 2013; 17: 175-9
2. Hex N, Bartlett C, Wright D, et al. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med 2012; 29: 855-62
3. Diabetes Control and Complications Trial Research Group (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
4. National Institute for Health and Care Excellence. TA151 Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus. London, UK: National Institute for Health and Care Excellence; 2008. http://www.nice.org.uk/guidance/ta151/chapter/1-guidance. Accessed October 28, 2014
5. Diabetes UK. The United Kingdom insulin pump audit-service level data. London, UK: Diabetes UK; 2013. http://www.diabetes.org.uk/Documents/News/The-United-Kingdom-Insulin-Pump-Audit-May-2013.pdf. Accessed February 3, 2015
6. Pickup J. Insulin pumps. Int J Clin Pract Suppl 2011; 170: 16-19
7. Pickup JC, Keen H, Parsons JA, et al. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. BMJ 1978; i: 204-7
8. OConnell MA, Donath S, ONeal DN, et al. Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia 2009; 52: 1250
9. Raccah D, Sulmont V, Reznik Y, et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes. Diabetes Care 2009; 32: 2245
10. Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012; 55: 3155-62
11. Choudhary P, Shin J, Wang Y, et al. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care 2011; 34: 2023-5
12. Choudhary P, Ramasamy S, Green L, et al. Real-time continuous glucose monitoring significantly reduces severe hypoglycemia in hypoglycemia-unaware patients with type 1 diabetes. Diabetes Care 2013; 36: 4160-2
13. Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013; 369: 224-32
14. Ly TT, Nicholas JA, Retterath A, et al. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA 2013; 310: 1240-7
15. St Charles ME, Sadri H, Minshall ME, et al. Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada. Clin Ther 2009; 31: 657-67
16. St Charles M, Lynch P, Graham C, et al. A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective. Value Health 2009; 12: 674-86
17. Cohen N, Minshall ME, Sharon-Nash L, et al. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia. Pharmacoeconomics 2007; 25: 881-97
18. Roze S, Saunders R, Brandt A, et al. Health-economic analysis of real-time continuous glucose monitoring in people with Type 1 diabetes. Diabet Med 2015; 32: 618-26
19. Ly T, Brnabic AJM, Eggleston A, et al. A cost-effectiveness analysis of sensor-augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes. Value Health 2014; 17: 561-9
20. Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ 2011; 343: d3805
21. Lynch P, Attvall S, Persson S, et al. Routine use of personal glucose monitoring system with insulin pump use in Sweden. Abstract presented at the 48th annual meeting of the European Association for the Study of Diabetes. 1-5 October 2012, Berlin, Germany. Diabetologia 2012;55(1 Suppl)S432
22. Nørgaard K, Scaramuzza A, Bratina N, et al. Routine sensor-augmented pump therapy in type 1 diabetes: the INTERPRET study. Diabetes Technol Ther 2013; 15: 273-80
23. Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006; 22: 1523-34
24. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004; 20 (1 Suppl): S5-26
25. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004; 20 (1 Suppl): S27-40
26. McEwan P, Foos V, Palmer JL, et al. Validation of the IMS CORE Diabetes Model. Value Health 2014; 17: 714-24
27. National Institute for Health and Care Excellence. NICE clinical guideline 48. London, UK: National Institute for Health and Care Excellence; 2007. http://www.nice.org.uk/guidance/cg48/resources/guidance-mi-secondary-prevention-secondary-prevention-in-primary-and-secondary-care-for-patients-following-a-myocardial-infarction-pdf. Accessed December 19, 2014
28. Dyer MT, Goldsmith KA, Khan SN, et al. Clinical and cost-effectiveness analysis of an open label, single-centre, randomised trial of spinal cord stimulation (SCS) versus percutaneous myocardial laser revascularisation (PMR) in patients with refractory angina pectoris: The SPiRiT trial. Trials 2008; 9: 40
29. Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ 2009; 180: 400-7
30. National Institute for Health and Care Excellence. NICE technology appraisal guidance 94. London, UK: NICE; 2006. http://www.nice.org.uk/guidance/ta94/resources/guidance-statins-for-the-prevention-of-cardiovascular-events-pdf. Accessed December 19, 2014
31. Youman P, Wilson K, Harraf F, et al. The economic burden of stroke in the United Kingdom. Pharmacoeconomics 2003; 21 (1 Suppl): 43-50
32. UK National Institute for Health and Care Excellence. NICE clinical guideline 73. London, UK: UK National Institute for Health and Care Excellence; 2008. http://www. nice.org.uk/guidance/cg73/resources/guidance-chronic-kidney-disease-early-identification-and-management-of-chronic-kidney-disease-in-adults-in-primary-and-secondary-care-pdf. Accessed December 19, 2014
33. UK National Institute for Health and Care Excellence. NICE clinical guideline 87. Type 2 diabetes. The management of type 2 diabetes. London, UK: UK National Institute for Health and Care Excellence; 2008. https://www.nice.org.uk/guidance/cg87/resources/guidance-type-2-diabetes-pdf. Accessed December 19, 2014
34. Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003; 20: 442-50
35. Meads C, Hyde C. What is the cost of blindness Br J Ophthalmol 2003; 87: 1201-4
36. Ghatnekar O, Willis M, Persson U. Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries. J Wound Care 2002; 11: 70-4
37. UK Government Department of Health. UK National Health Service reference costs 2012-2013. London, UK: UK Government Department of Health, 2013. https://www.gov.uk/government/publications/nhs-reference-costs-2012-to-2013. Accessed December 19, 2014
38. British National Formulary 63 (March 2012). London, UK; 2012. https://www.medicinescomplete.com/about/publications.htm. Accessed December 19, 2014
39. Beaudet A, Clegg J, Thuresson PO, et al. Review of utility values for economic modeling in type 2 diabetes. Value Health 2014; 17: 462-70
40. National Institute for Health and Clinical Excellence. Discounting of health benefits in special circumstances. London, UK: National Institute for Health and Clinical Excellence; 2011. http://www.nice.org.uk/media/955/4F/Clarification-to-section-5.6-of-the-Guide-to-Methods-of-Technology-Appraisals.pdf. Accessed December 14, 2014
41. Böhme P, Bertin E, Cosson E, et al., GEODE group. Fear of hypoglycemia in patients with type 1 diabetes: do patients and diabetologists feel the same way Diabetes Metab 2013; 39: 63-70
42. Fidler C, Elmelund Christensen T, et al. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ 2011; 14: 646-55
43. McQueen RB, Ellis SL, Maahs DM, et al. Association between glycated hemoglobin and health utility for Type 1 diabetes. Patien 2014; 7: 197-205